Exebacase in Addition to Daptomycin against MRSA-Reference-Cited by-同舟云学术

Exebacase in Addition to Daptomycin against MRSA

Published:2021-10-18 Issue:11 Volume:65 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Kebriaei Razieh¹,Stamper Kyle C.¹,Lev Katherine L.¹,Morrisette Taylor¹,Abdul-Mutakabbir Jacinda C.¹,Schuch Raymond²^ORCID,Lehoux Dario²,Rybak Michael J.¹³⁴^ORCID

Affiliation:

1. Anti-Infective Research Laboratory, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA

2. ContraFect Corporation, Yonkers, New York, USA

3. School of Medicine, Wayne State University, Detroit, Michigan, USA

4. Detroit Receiving Hospital, Detroit, Michigan, USA

Abstract

Exebacase is a lysin (cell wall hydrolase) with direct lytic activity against Staphylococcus aureus including methicillin-resistant S. aureus (MRSA). Time-kill analysis experiments illustrated bactericidal activity of exebacase-daptomycin against MRSA strains MW2 and 494.

Funder

HHS | National Institutes of Health

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.00128-21

Reference27 articles.

1. Invasive Methicillin-Resistant Staphylococcus aureus Infections in the United States

2. National Burden of Invasive Methicillin-ResistantStaphylococcus aureusInfections, United States, 2011

3. Methicillin-Resistant Staphylococcus aureus Therapy: Past, Present, and Future